CT image analysis of the vertebral trabecular network in vivo

Chevalier, Florent; Laval-Jeantet, A. M.; Laval-Jeantet, M; Bergot, C.

doi:10.1007/bf00296208

Cited by 113 publications

(68 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few cross-sectional studies using clinical CT scanners to assess vertebral trabecular structure in vivo (21)(22)(23) aiming at fracture discrimination or diagnosis of osteoporosis. In comparison with our work, all of these studies used larger voxel sizes, in the order of 400 m in plane, and a slice thickness of 1.0-1.5 mm.…”

Section: Discussionmentioning

confidence: 99%

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study

Graeff

Timm

Nickelsen

et al. 2007

Journal of Bone and Mineral Research

145

107

View full text Add to dashboard Cite

We introduce a method for microstructural analysis of vertebral trabecular bone in vivo based on HRCT. When applied to monitor teriparatide treatment, changes in structural variables exceeded and were partially independent of changes in volumetric BMD.Introduction: Monitoring of osteoporosis therapy based solely on bone densitometry is insufficient to assess anti-fracture efficacy. Assessing bone microstructure in vivo is therefore of importance. We studied whether it is possible to monitor effects of teriparatide on vertebral trabecular microstructure independent of BMD by high-resolution CT (HRCT). Materials and Methods:In a subset of 65 postmenopausal women with established osteoporosis who participated in the EUROFORS study, HRCT scans of T 12 , quantitative CT of L 1 -L 3 , and DXA of L 1 -L 4 were performed after 0, 6, and 12 mo of teriparatide treatment (20 g/d). We compared BMD and 3D microstructural variables in three groups of women, based on prior antiresorptive treatment: treatment-naïve; pretreated; and pretreated women showing inadequate response to treatment. Results: We found statistically highly significant increases in most microstructural variables and BMD 6 mo after starting teriparatide. After 12 mo, apparent bone volume fraction (app. BV/TV) increased by 30.6 ± 4.4% (SE), and apparent trabecular number (app. Tb.N.) increased by 19.0 ± 3.2% compared with 6.4 ± 0.7% for areal and 19.3 ± 2.6% for volumetric BMD. The structural changes were partially independent of BMD as shown by a significantly larger standardized increase and a standardized long-term precision at least as good as DXA. Patients who had shown inadequate response to prior osteoporosis treatment did show improvements in BMD and structural measures comparable to treatment-naïve patients. Conclusions: HRCT is a feasible method for longitudinal microstructural analysis of human vertebrae in vivo, offers information beyond BMD, and is sufficiently precise to show profound effects of teriparatide after 12 mo.

show abstract

Section: Discussionmentioning

confidence: 99%

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study

Graeff

Timm

Nickelsen

et al. 2007

Journal of Bone and Mineral Research

145

107

View full text Add to dashboard Cite

show abstract

“…no, (42) yes (43) Yes (125) Variable: yes, (84,166) no (22) BMD (g/cm 3 ; ±SD) Cancellous-vertebra 0.12-0.14 (82,167) 0.30-0.39 (58) 0.39-0.43 (171) 0.39-0.42 (107) 0.48-0.60 (58,82,168) Cancellous-distal femur 0.43-0.46 (168) 0.44 ± 0.16 (168) - (173) Similarity of bone attributes to humans ; ± SD (when vBMD data not available).…”

Section: Yesmentioning

confidence: 99%

Review of Nonprimate, Large Animal Models for Osteoporosis Research

Reinwald

Burr

2008

Journal of Bone and Mineral Research

134

105

View full text Add to dashboard Cite

Large animal models are required for preclinical prevention and intervention studies related to osteoporosis research. The challenging aspect of this requirement is that no single animal model exactly mimics the progression of this human-specific chronic condition. There are pros and cons associated with the skeletal, hormonal, and metabolic conditions of each species that influence their relevance and applicability to human physiology. Of all larger mammalian species, nonhuman primates (NHPs) are preeminent in terms of replicating important aspects of human physiology. However, NHPs are very expensive, putting them out of reach of the vast majority of researchers. Practical, cost-effective alternatives to NHPs are sought after among ungulate (porcine, caprine, and ovine) and canine species that are the focus of this review. The overriding caveat to using large lower-order species is to take the time in advance to understand and appreciate the limitations and strengths of each animal model. Under these circumstances, experiments can be strategically designed to optimize the potential of an animal to develop the cardinal features of postmenopausal bone loss and/or yield information of relevance to treatment.

show abstract

“…Bone mineral density (BMD) has been shown to be one of the most important contributing factors to bone strength and a good predictor of fracture risks in osteoporosis [4,9,19,25,28]. However, many recent studies have shown that BMD alone may not be sufficient to determine the strength of cancellous bone and that the trabecular architecture may also be an important factor in determining bone strength and individual risk of fractures [3,5,11,33,34].…”

Section: Introductionmentioning

confidence: 99%

Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy

KASUKAWA¹

2004

Journal of Orthopaedic Research

View full text Add to dashboard Cite

The purpose of this study was to determine whether h-PTH (1 -34) treatment would recover cancellous bone connectivity and bone strength in ovariectomized (OVX) or ovariectomized and sciatic-neurectomized (OVX + NX) rats. Seven-month-old female Wistar rats were treated with h-PTH or vehicle (6.0 pg/kg, six times a week, subcutaneously) for four weeks beginning 4, 8, or 12 weeks after OVX or OVX + NX. These were compared to age-matched baseline and sham-operated groups. Right tibiae were used for bone histomorphometry and node-strut analysis, and left tibiae were used for mechanical testing. The bone formation rates in the OVX and OVX + NX rats treated with h-PTH were significantly higher than those in their baseline controls. h-PTH treatment increased the node numbers and failure energies in the OVX rats, compared to their baseline controls, at all time points. However, in the OVX + NX rats, the effects of h-PTH treatment on the node number and failure energy were observed only at four weeks after surgery, but not at eight weeks or 12 weeks after surgery. These results suggest that the lowest limit, at which trabecular connectivity and bone strength are able to be restored by h-PTH, occurred between four and eight weeks in OVX + NX rats, but not in OVX rats.h-PTH cannot recover trabecular connectivity and bone strength in advanced osteopenia.

show abstract

CT image analysis of the vertebral trabecular network in vivo

Cited by 113 publications

References 13 publications

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study

Review of Nonprimate, Large Animal Models for Osteoporosis Research

Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy

Contact Info

Product

Resources

About